Restaging oesophageal cancer after neoadjuvant therapy with 18 F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery

Objectives It is unknown whether restaging oesophageal cancer after neoadjuvant therapy with positron emission tomography-computed tomography (PET-CT) is more sensitive than contrast-enhanced CT for disease progression. We aimed to determine this and stratify risk.